AbbVie inks multi-year AI drug discovery deal with Iambic Therapeutics (ABBV:NYSE)

AbbVie inks multi-year AI drug discovery deal with Iambic Therapeutics (ABBV:NYSE)

AbbVie and Iambic Therapeutics partner to use AI drug discovery for immunology, neuroscience, and oncology—milestones, royalties, and new candidates.

Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Lambic

AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.